Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PRCS -- Ignore unavailable to you. Want to Upgrade?

To: Mark Bong who wrote (21)	4/8/2001 6:27:13 PM
From: tuck	Read Replies (1) \| Respond to of 78

Now the owner of some PRCS shares. Sold puts, and they got exercised before I rolled. Pretty unusual, that. I sort of like these reviews, as they sometimes have market info hard to come by elsewhere: >>Technology evaluation: Abarelix, Praecis pharmaceuticals. Curr Opin Mol Ther 2000 Oct;2(5):579-85 (ISSN: 1464-8431) Doehn C; Jocham D [Find other articles with these Authors] Department of Urology, Medical University of Luebeck, Ratzeburger Allee 160, 23538 Luebeck, Germany. doehn@medinf.mu-luebeck.de. Abarelix (PPI-149) is a luteinizing hormone-releasing hormone (LHRH) receptor antagonist under development by Praecis, Amgen and Sanofi-Synthelabo for the potential treatment of prostate cancer, breast cancer and hormone-related disorders [285672,328910]. Abarelix has entered phase III clinical trials for hormonally responsive prostate cancer [311887], and a sustained-release formulation is in a phase I/II clinical trial for endometriosis [317822]. In June 1997, Praecis entered into a collaboration with Sanofi-Synthelabo for the continued development and future marketing of Abarelix for the treatment of prostate cancer and other hormone-related disorders in Europe [248307]. In June 1998, Roche gained marketing rights in the US and elsewhere, under a joint development agreement [289677], which was later terminated. In March 1999, Amgen gained rights to develop Abarelix in the US, Canada, Australia, Asia and other secondary markets [317822]. Sanofi-Synthelabo expects to launch the compound in Europe in 2001 [345341,346302]. In March 1999, Merrill Lynch predicted sales in 2001 of US$75 million, with peak sales of up to US$400 million [336561]. In October 1999, Merrill Lynch predicted sales in 2003 of EUR 100 million [346209] and Lehman Brothers predicted sales of US$50 million in 2002 rising to a peak of US$150 million in 2010 [346267]. Language: English MEDLINE Indexing Date: 200103<< snip Cheers, Tuck